DaVita Inc. stock gains after data breach settlement and partnership expansion

Published on 09/02/2026 at 21:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DaVita Inc. stock has climbed sharply after a strong move on the New York Stock Exchange, while investors weigh a data breach settlement and an expanded partnership with Humana for future growth and risk balance.

Draufsicht auf Aktien-Zertifikat, Stethoskop, Dialyseschlauch und Analysediagramme auf Marmor — Flatlay-Arrangement mit Aktien-Zertifikat, ISIN-Karte und medizinischen Utensilien der DaVita Inc. US23918K1088 auf Marmor, Illustration mit AI erstellt.

DaVita Inc. stock (ISIN US23918K1088) closed at 192.44 US dollars on the New York Stock Exchange on September 1, 2026, up 9.34% from the previous close of 176.01 US dollars according to market data from Yahoo Finance. This sharp move follows fresh attention on DaVita from investors as they digest both a legal settlement related to a past data breach and a strategic expansion of the company’s partnership with Humana reported on September 2, 2026.

Stock reaction and valuation debate

According to the latest Yahoo Finance quote, DaVita’s closing price of 192.44 US dollars on September 1, 2026 came after an intraday high at the same level and an open of 175.00 US dollars, underscoring strong buying interest despite broader weakness in US equities.

A valuation analysis published on September 2, 2026 by Simply Wall St notes that a widely followed fair value estimate for DaVita stands at about 218 US dollars per share, compared with a recent close around 176.14 US dollars discussed in that report, implying a valuation gap of roughly 41.86 US dollars or about 23.8% at that time.

Legal settlement over prior data breach

The legal overhang from a previous data breach is in focus again after DaVita agreed to pay 15 million US dollars to settle claims linked to an incident that affected approximately 2.7 million people, as reported on September 2, 2026 by Healthcare Dive. The settlement is associated with a proposed class action lawsuit and represents a notable cash outlay, but also provides greater clarity on DaVita’s legal exposure.

For investors, the settlement amount of 15 million US dollars is modest compared with DaVita’s multibillion dollar market capitalization and typical annual revenue base, but the fact that 2.7 million individuals were impacted underscores the importance of data security and compliance for healthcare providers serving sensitive patient populations.

Go deeper

DaVita Inc. stock and fundamentals in detail

For more background on DaVita Inc. stock and its latest filings, including historical earnings and guidance, you can access an overview of news and regulatory disclosures linked to the ISIN.

Dialysis services and Humana partnership

DaVita Inc. is one of the largest providers of kidney dialysis services in the United States, operating thousands of centers that deliver life sustaining treatments to patients with end stage renal disease.

The company has been expanding its collaboration with health insurers to stabilize patient volumes and reimbursement, and a recent analysis highlights an expanded partnership with Humana, one of the major US health insurance carriers, which is expected to reinforce DaVita’s managed care relationships according to the Simply Wall St report dated September 2, 2026.

Stock level and investor perspective

From an investor perspective, the closing price of 192.44 US dollars on September 1, 2026 situates DaVita Inc. stock meaningfully above the 176.01 US dollar level referenced as the prior close on August 31, 2026 in Yahoo Finance data, marking a gain of 16.43 US dollars or 9.34% in one trading day.